RTP Mobile Logo
Proceedings from the 11th Annual Winter Lung Cancer Conference
Released May 2014

Proceedings from a live event featuring traditional didactic faculty presentations and case-based panel discussions focused on all factors that influence multidisciplinary treatment decision-making for lung cancer. Featuring perspectives from Drs David P Carbone, David R Gandara, John V Heymach, Mark G Kris, Rogerio C Lilenbaum, Thomas J Lynch Jr, Geoffrey R Oxnard, Suresh S Ramalingam, Lecia V Sequist, Mark A Socinski, Eric Vallières, Gregory Videtic and Heather Wakelee. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of medical oncologists and other healthcare providers involved in the treatment of lung cancer.

    OVERVIEW OF ACTIVITY
    Lung cancer is a devastating disease that accounts for approximately 13% of new cancer cases and more cancer-related deaths among both men and women than any other tumor type. In the year 2014, it is estimated that 224,210 individuals will be diagnosed and 159,260 individuals will die from the disease. The plethora of available cytotoxic chemotherapies exhibiting activity in lung cancer has increased substantially over the past several years, and development of new therapeutic strategies beyond cytotoxic chemotherapy has been the focus of extensive recent research and has led to an explosion in lung cancer genetic and biologic knowledge. The advent of these next-generation targeted treatments presents new promise of both efficacy and enhanced safety for patients with lung cancer but also challenges practicing oncologists to appropriately select individuals who may benefit from these agents and to determine how to integrate such therapies, as they become available, into standard lung cancer treatment algorithms.

    This unique educational activity delivers highly applicable current clinical information delving into the personalized management of this challenging disease and provides clinicians with a concise, easy-to-understand resource to facilitate knowledge and application of optimal diagnostic and therapeutic approaches.

    LEARNING OBJECTIVES

    • Develop an evidence-based strategy for the treatment of localized non-small cell lung cancer (NSCLC), exploring the role of adjuvant systemic therapy.
    • Apply the results of emerging clinical research to the recommendation of multimodality therapy for patients with Stage III NSCLC.
    • Compare and contrast the benefits and risks of combination chemobiologic, doublet and single-agent chemotherapy regimens when developing treatment plans for patients with advanced NSCLC.
    • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line and subsequent treatment approaches for patients with metastatic NSCLC.
    • Identify patients with metastatic NSCLC who may experience clinical benefit from the addition of continuation or switch maintenance biologic therapy and/or chemotherapy.
    • Recognize the effect of NSCLC tumor-specific mutations on relative response or resistance to treatment with tyrosine kinase inhibitors, monoclonal antibodies and other emerging molecular-targeted agents.
    • Differentiate among existing and emerging molecular-targeted therapies, and effectively integrate new compounds, when available, into individualized lung cancer treatment strategies.
    • Formulate management strategies for limited- or extensive-stage small cell lung cancer, considering the contributory roles of surgery, radiation therapy (local and prophylactic cranial irradiation) and chemotherapy.
    • Recall the design of ongoing clinical trials evaluating novel investigational agents in lung cancer, and counsel appropriately selected patients about availability and participation.

    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. The participant should watch the video.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    David P Carbone, MD, PhD
    Professor of Internal Medicine
    Director, James Thoracic Center
    Columbus, Ohio

    Consulting Agreements: Amgen Inc, Astellas, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Bristol-Myers Squibb Company.

    David R Gandara, MD
    Professor of Medicine
    Director, Thoracic Oncology Program
    Senior Advisor to Director
    UC Davis Comprehensive Cancer Center
    Sacramento, California

    Advisory Committee: Synta Pharmaceuticals Corp; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Response Genetics Inc, Sanofi, Synta Pharmaceuticals Corp; Contracted Research: Abbott Laboratories, Bristol-Myers Squibb Company, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc.

    John V Heymach, MD, PhD
    Professor and Chair
    Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, Synta Pharmaceuticals Corp; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline.

    Mark G Kris, MD
    William and Joy Ruane Chair in Thoracic Oncology
    Attending Physician
    Thoracic Oncology Service
    Memorial Sloan-Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: ARIAD Pharmaceuticals Inc, Clovis Oncology, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Puma Biotechnology Inc, Roche Laboratories Inc; Contracted Research: Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc.

    Rogerio C Lilenbaum, MD
    Professor of Medicine
    Yale School of Medicine
    Chief Medical Officer
    Smilow Cancer Hospital
    Yale Cancer Center
    New Haven, Connecticut

    Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology.

    Thomas J Lynch Jr, MD
    Director, Yale Cancer Center
    Physician-in-Chief
    Smilow Cancer Hospital at Yale-New Haven
    Richard and Jonathan Sackler Professor of Internal Medicine
    New Haven, Connecticut

    Board of Directors: Infinity Pharmaceuticals Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merck, Roche Laboratories Inc; Other Remunerated Activities: Partners HealthCare.

    Geoffrey R Oxnard, MD
    Assistant Professor of Medicine
    Harvard Medical School
    Lowe Center for Thoracic Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: Aveo Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Honoraria: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd.

    Suresh S Ramalingam, MD
    Professor of Hematology and Medical Oncology
    Director, Division of Medical Oncology
    Emory University
    Winship Cancer Institute
    Atlanta, Georgia

    Advisory Committee: AstraZeneca Pharmaceuticals LP; Consulting Agreements: ARIAD Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Lilly, Novartis Pharmaceuticals Corporation; Contracted Research: Bristol-Myers Squibb Company.

    Lecia V Sequist, MD, MPH
    Associate Professor of Medicine
    Harvard Medical School
    Center for Thoracic Cancers
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, GlaxoSmithKline, Merrimack Pharmaceuticals.

    Mark A Socinski, MD
    Professor of Medicine and Thoracic Surgery
    Director, Lung Cancer Section
    Division of Hematology/Oncology
    Co-Director, UPMC Lung Cancer
    Center of Excellence
    Co-Director, Lung and Thoracic Malignancies Program
    University of Pittsburgh
    UPMC Cancer Pavilion
    Pittsburgh, Pennsylvania

    Contracted Research: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly, Merrimack Pharmaceuticals, Onyx Pharmaceuticals Inc, Pfizer Inc; Data and Safety Monitoring Board: Millennium: The Takeda Oncology Company; Speakers Bureau: Celgene Corporation, Genentech BioOncology.

    Eric Vallières, MD
    Surgical Director, Lung Cancer Program
    Medical Director, Division of Thoracic Surgery
    Swedish Cancer Institute
    Seattle, Washington

    Advisory Committee: GlaxoSmithKline; Consulting Agreements: GlaxoSmithKline, Myriad Genetics Inc, Uptake Medical; Speakers Bureau: Astellas, Genentech BioOncology, GlaxoSmithKline, Synthes Inc.

    Gregory Videtic, MD, CM
    Associate Professor of Medicine
    Cleveland Clinic Lerner College of Medicine
    Staff Physician
    Department of Radiation Oncology
    The Cleveland Clinic
    Cleveland, Ohio

    No real or apparent conflicts of interest to disclose.

    Heather Wakelee, MD
    Associate Professor of Medicine
    Division of Oncology
    Stanford University School of Medicine
    Stanford Cancer Institute
    Stanford, California

    Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Xcovery.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Novartis Pharmaceuticals Corporation and VisionGate Inc..

    Hardware/Software Requirements:
    A high-speed Internet connection 
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2014
    Expiration date:
    May 2015

    CME credit is no longer available for this issue

Acknowledge and close

View video: